Today, and welcome to the Myriad Genetics annual meeting of stockholders. I would now like to turn the conference over to Ms. Louise Phanstiel. Please go ahead. Thank you, Operator. Welcome to the 2025 annual meeting of stockholders of Myriad Genetics. I'm Louise Phanstiel, Chair of the Board, and it is my pleasure to welcome you. It is 8:00 A.M. Mountain Time, and in accordance with the notice of the meeting, I call to order the 2025 annual meeting of stockholders of Myriad Genetics. An agenda that outlines the order of business and rules of conduct have been made available on the website. We will conduct this meeting in accordance with the agenda and those rules. There will be an opportunity for questions later in the webcast. Please adhere to the rules of conduct attached to your agenda in asking questions or making comments at that time. The matters on which stockholders at the meeting are voting are to: elect three directors, ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the year ending 2025, approve on an advisory basis the compensation of our named executive officers, approve an amendment to our 2017 Employee, Director, and Consultant Equity Incentive Plan to replenish the share pool for equity incentive grants, and lastly, transact other business that may properly come before the meeting. Before proceeding to the business of the meeting, I'd like to introduce our directors who are present on the webcast, including those who are up for election. Sam Raha joined Myriad in December 2023 and served as Myriad's Chief Operating Officer until he was appointed as a director and our Chief Executive Officer in April 2025. Paul Bissaro joined Myriad as a director in October of 2022. Mark Davis joined Myriad as a director in December 2024. Heinrich Reisman, Ph.D., joined Myriad as a director in June of 2010. Rashmi Kumar was appointed as a director in September 2020. Lee Newcomer, M.D., joined the Myriad Board of Directors in September 2019. Colleen Ratten was appointed to our Board of Directors in September 2019. Dan Skarvonski, M.D., Ph.D., has served as a director since July 2020. I joined the Board of Directors in September 2009 and have served as the Chair of the Board since March 2020. I'm also pleased to announce that we have members of the executive team of Myriad Genetics joining us on the webcast today. Biographical information for each of our officers and directors, including their history with the company, is included in the proxy materials. Also with us today is Remco Bartman, representing Ernst & Young LLP, the company's independent auditors. Remco will be available during the question and answer session later in the webcast to respond to appropriate questions. The company has appointed Ben Wheeler to act as Inspector of Elections. Mr. Wheeler has taken the oath of Inspector of Elections earlier today. We also have Justin Hunter, our Corporate Secretary, here with us today. Justin will serve as the Secretary of the meeting and will record the proceedings. This meeting is held pursuant to a notice of each stockholder of record at the close of business on April 8, 2025, which was made available on the internet and mailed to certain stockholders on or about April 9, 2025. Only stockholders of record at the close of business on April 8 are entitled to vote at this meeting. I now ask our Inspector of Elections, Mr. Wheeler, to report on the presence of a quorum. On April 8th, 2025, the number of shareholders of common stock issued and outstanding and entitled to vote was 92,171,423. A majority of these shares, or 46,085,712 shares, constitutes a quorum. Substantially in excess of that number of shares is represented at this meeting either in person or by proxy. I hereby declare a quorum present at the meeting. On behalf of the Board of Directors of the company, thank you to all stockholders who completed their proxy. If you are a stockholder of record on April 8, 2025, and wish to vote now, you can do so by utilizing the interface on the webcast page by hitting the vote button. It is 8:04 A.M. Mountain Time and the polls are now open. The first matter to be acted upon by stockholders is the election of three directors. Heinrich Reisman, Ph.D., Sam Raha, and Colleen F. Ratten have been nominated by the Board for election at this meeting to serve as directors in Class two. The Class two directors' term will end at the annual meeting to be held in 2028. I've introduced the nominees, and additional information about the nominees is contained in the proxy statements. I declare that the Class 2 directors duly nominated. The company has not received notice of any other nominations as required under the bylaws. Therefore, I declare the nominations closed. For stockholders voting on the webcast, please do so now. The second matter being submitted to stockholders for action is the ratification of the selection by the Audit and Finance Committee of the Board of Directors of Ernst & Young LLP as auditors of the company's financial statements for the fiscal year ending December 31, 2025. The Audit and Finance Committee of the Board of Directors is assigned the responsibility of appointing the company's auditors. The committee consists entirely of directors who are independent of corporate management. In its deliberations, the committee took note of the fact that it has worked closely and met on a regular basis with Ernst & Young during the past year, and the committee has had substantial opportunity to evaluate their work and found it to be satisfactory. The Audit and Finance Committee recommends the ratification of its appointment of Ernst & Young to audit the financial statements for the fiscal year ending December 31, 2025. Stockholders voting on the webcast, please do so now. The next matter to be acted on by stockholders is an advisory vote on the compensation of the company's named executive officers. Detailed disclosures regarding the company's compensation policies can be found in the proxy statement under the section entitled Executive Compensation. Because this vote is advisory, the results will not be binding on the company's Compensation and Human Capital Committee or the Board of Directors. However, both the Compensation and Human Capital Committee and the Board will review the voting results and take them into consideration when making future decisions regarding the compensation of the company's named executive officers. Stockholders voting on the webcast, please do so now. The next matter to be acted on by stockholders is the proposed amendment to our 2017 Employee, Director, and Consultant Equity Incentive Plan to increase the aggregate number of shares of common stock available for grant under the 2017 plan by an additional 6.5 million shares. On March of 2025, the Board approved the proposed amendment to the 2017 plan and recommended that stockholders approve it as well. Additional shares of our common stock must be authorized under the 2017 plan to enable us to continue granting equity incentive compensation to our employees, executive officers, and directors. Detailed information regarding the proposed amendment and the 2017 plan can be found in the proxy statement under Proposal Number four. Stockholders voting on the webcast, please do so now. It is 8:08 A.M. Mountain Time. The polls are now closed for each of the matters to be voted on at this meeting. For the Inspector of Elections, please report the results of the balloting. We have completed a preliminary count of the ballots and present the following. For Proposal Number one, election of directors, a majority of the shares voted was cast for the election of each of Heinrich Reisman, Ph.D., Samraat Raha, and Colleen F. Ratten to serve until the 2028 annual meeting. The results of the voting for Proposal Number two, appointment of auditors, are 78,614,062 votes cast for the ratification of appointment of Ernst & Young LLP to serve as the company's independent public accountants for the fiscal year ending December 31, 2025, which is more than a majority of the shares voted with respect to this proposal. The results of the voting for Proposal Number three, compensation of named executive officers, are 67,755,156 votes cast for the proposal or in support of the compensation of our named executive officers, which is more than a majority of the shares voted with respect to this proposal. The results of the voting for Proposal Number four, proposed amendment to the 2017 Employee, Director, and Consultant Equity Incentive Plan as amended to replenish the share pool for equity incentive grants, are 69,476,724 votes cast for the proposal, which is more than a majority of the shares voted with respect to this proposal. Subject to final vote tabulation, I hereby declare that the nominees for directors have been duly elected. The appointment of Ernst & Young as the company's independent public accounting firm for the fiscal year ending December 31, 2025, has been duly ratified. A majority of the shares voted in favor of the advisory vote regarding the compensation of the company's named executive officers, and the amendment to the 2017 Employee, Director, and Consultant Equity Incentive Plan has been approved by the stockholders. After the final tabulation of votes has been completed, the results will be filed on Form eight-K and will be placed in the minutes of this meeting. This concludes the formal portion of our meeting. I would again like to express my appreciation to the stockholders who attended the meeting and voted, as well as those who submitted their proxy but were not able to be present in the meeting via this webcast. There being no further business to come before the meeting, the annual meeting of stockholders is now formally adjourned. We invite you to ask questions that you may have. We will only take questions from stockholders of record or from an individual or entity named in a proxy given by a stockholder of record as of April 8, 2025, and properly filed with the Corporate Secretary prior to the meeting. Please be advised that management's remarks and responses to questions and comments may contain some forward-looking statements. In compliance with the Private Securities Litigation Reform Act of 1995, I caution you that actual results may differ significantly and adversely from results discussed in the forward-looking statements. Forward-looking information is inherently subject to risk and uncertainties that could cause results or events to differ materially and adversely from those described in or implied by forward-looking statements due to a variety of factors and risks. Factors and risks that may cause a difference, including those set forth from time to time in the company's SEC filings included in the annual report on Form 10-K for the year ending December 31, 2024, and its reports on Form 10-Q and Form eight-K filed with the SEC. With that, do we have any stockholder questions? There are no stockholder questions. Since there are no questions, the annual meeting of stockholders is now officially adjourned. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.